Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912246633> ?p ?o ?g. }
- W2912246633 endingPage "2934" @default.
- W2912246633 startingPage "2934" @default.
- W2912246633 abstract "Abstract Background: Hodgkin Lymphoma (HL) is characterized by an inflammatory background and it has been demonstratedthat the reactive myeloid cells may exert an immune suppressive effect that favors progression of disease. The easily measurable NLR, the ratio between absolute neutrophils counts (ANC) and absolute lymphocyte count (ALC) and LMR, the ratio between ALC and absolute monocyte count (AMC) have been reported to reflect both the systemic inflammation and the myeloid associated immune suppression. We previously identified NLR, and to a lesser extend LMR, at baseline, as predictor of progression free survival (PFS) in HL patients. Objectives: To validate NLR>6 and LMR≤2 as predictor of clinical outcome at diagnosis in the context of a prospective clinical trial of newly diagnosed advanced stage (aa) HL patients treated upfront with a PET-2 risk-adapted strategy. Methods: According to HD 0607 trial (Gallamini, JCO 2018), 782 advanced-stage HL patients were treated with 2 ABVD courses and a PET-2 performed afterwards. PET-2 positive (PET-2+) patients (N=149) were randomized to either BEACOPP escalated (Be) plus BEACOPP baseline (Bb) (4+4 courses) or Be+Bb (4+4) and Rituximab. PET-2 negative (PET-2-) patients were treated with 4 additional ABVD and, upon CR achievement, randomized to either consolidation radiotherapy on the sites of initial bulky disease or no further treatment. PET scans were centrally reviewed by an expert panel by Blinded Independent Central Review. Results: Median NLR at baseline was 5.7 (IQ range 3.8-8.3). NLR was higher in younger patients (<45 years, p=0.0005), in females (p=0.0027) and in patients with B symptoms (p<0.0001), bulky disease (>7 cm, p<0.0001) and high IPS (p<0.0001). LMR was lower in males (p=0.01) and in patients with B symptoms (p<0.0001), bulky disease (p<0.0001) and high IPS (≥3, p<0.0001). Neither NLR nor LMR values were associated with Ann Arbor stage. Higher NLR (p=0.0001 and p=0.0003) and lower LMR (p=0.01, and p=0.02) were respectively associated with a PET-2+ (DS score 4 and 5) and failure to achieve long-term disease control. Receiving operator curve (ROC) confirmed 6 as the cut-off of NLR to predict clinical outcome with 59% (95% C.I. 51-68) sensitivity and 57% (95% C.I. 53-61) specificity (AUC 0.59). Negative predictive value of LMR, with cutoff of 2, was 79% with 40% (95% C.I. 31-48) sensitivity and 50% (95% C.I. 46-54) specificity (AUC 0.56). NLR was >6 in 88/149 (59%) PET-2+ and in 269/628 (43%) PET-2- patients. By univariate and multivariate analysis, bulky disease, IPS≥3, NLR>6 were strong independent predictors of early PET-2 response after ABVD (table I). Only PET-2 positivity (p<0.0001) and IPS≥3 (p=0.0001) were independent predictors of PFS by multivariate analysis. Focusing on PET-2 negative patients, we found that patients with NLR>6 had an inferior 3-years PFS compared to patients with NLR ≤6 (84% versus 89%, p=0.003), while there was no stastical difference based on LMR status. Conclusion: At diagnosis, the presence of bulky disease, IPS score ≥3 and NLR>6 are independent predictors of early ABVD response (PET-2 positivity) and this information should be considered when selecting the initial treatment for aaHL patients. Disclosures Di Raimondo: Celgene: Honoraria; Takeda: Honoraria, Research Funding. Trentin:Janssen: Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria; Gilead: Research Funding. Gallamini:Takeda: Consultancy, Speakers Bureau. Rambaldi:Amgen Inc.: Consultancy; Celgene: Consultancy; Roche: Consultancy; Italfarmaco: Consultancy; Omeros: Consultancy; Pfizer: Consultancy; Novartis: Consultancy." @default.
- W2912246633 created "2019-02-21" @default.
- W2912246633 creator A5001591385 @default.
- W2912246633 creator A5013236194 @default.
- W2912246633 creator A5015840872 @default.
- W2912246633 creator A5018769545 @default.
- W2912246633 creator A5026242819 @default.
- W2912246633 creator A5030721257 @default.
- W2912246633 creator A5030934542 @default.
- W2912246633 creator A5034393745 @default.
- W2912246633 creator A5038898384 @default.
- W2912246633 creator A5039773395 @default.
- W2912246633 creator A5053560614 @default.
- W2912246633 creator A5055401685 @default.
- W2912246633 creator A5057705097 @default.
- W2912246633 creator A5058639394 @default.
- W2912246633 creator A5058765211 @default.
- W2912246633 creator A5059060009 @default.
- W2912246633 creator A5059488532 @default.
- W2912246633 creator A5065510950 @default.
- W2912246633 creator A5069410590 @default.
- W2912246633 creator A5071732201 @default.
- W2912246633 creator A5071803772 @default.
- W2912246633 creator A5077505240 @default.
- W2912246633 creator A5081254171 @default.
- W2912246633 creator A5084921812 @default.
- W2912246633 creator A5085410438 @default.
- W2912246633 creator A5087990801 @default.
- W2912246633 date "2018-11-29" @default.
- W2912246633 modified "2023-09-28" @default.
- W2912246633 title "Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol" @default.
- W2912246633 doi "https://doi.org/10.1182/blood-2018-99-115346" @default.
- W2912246633 hasPublicationYear "2018" @default.
- W2912246633 type Work @default.
- W2912246633 sameAs 2912246633 @default.
- W2912246633 citedByCount "0" @default.
- W2912246633 crossrefType "journal-article" @default.
- W2912246633 hasAuthorship W2912246633A5001591385 @default.
- W2912246633 hasAuthorship W2912246633A5013236194 @default.
- W2912246633 hasAuthorship W2912246633A5015840872 @default.
- W2912246633 hasAuthorship W2912246633A5018769545 @default.
- W2912246633 hasAuthorship W2912246633A5026242819 @default.
- W2912246633 hasAuthorship W2912246633A5030721257 @default.
- W2912246633 hasAuthorship W2912246633A5030934542 @default.
- W2912246633 hasAuthorship W2912246633A5034393745 @default.
- W2912246633 hasAuthorship W2912246633A5038898384 @default.
- W2912246633 hasAuthorship W2912246633A5039773395 @default.
- W2912246633 hasAuthorship W2912246633A5053560614 @default.
- W2912246633 hasAuthorship W2912246633A5055401685 @default.
- W2912246633 hasAuthorship W2912246633A5057705097 @default.
- W2912246633 hasAuthorship W2912246633A5058639394 @default.
- W2912246633 hasAuthorship W2912246633A5058765211 @default.
- W2912246633 hasAuthorship W2912246633A5059060009 @default.
- W2912246633 hasAuthorship W2912246633A5059488532 @default.
- W2912246633 hasAuthorship W2912246633A5065510950 @default.
- W2912246633 hasAuthorship W2912246633A5069410590 @default.
- W2912246633 hasAuthorship W2912246633A5071732201 @default.
- W2912246633 hasAuthorship W2912246633A5071803772 @default.
- W2912246633 hasAuthorship W2912246633A5077505240 @default.
- W2912246633 hasAuthorship W2912246633A5081254171 @default.
- W2912246633 hasAuthorship W2912246633A5084921812 @default.
- W2912246633 hasAuthorship W2912246633A5085410438 @default.
- W2912246633 hasAuthorship W2912246633A5087990801 @default.
- W2912246633 hasBestOaLocation W29122466331 @default.
- W2912246633 hasConcept C126322002 @default.
- W2912246633 hasConcept C143998085 @default.
- W2912246633 hasConcept C2776305933 @default.
- W2912246633 hasConcept C2776694085 @default.
- W2912246633 hasConcept C2776755627 @default.
- W2912246633 hasConcept C2779338263 @default.
- W2912246633 hasConcept C2779429289 @default.
- W2912246633 hasConcept C2780653079 @default.
- W2912246633 hasConcept C71924100 @default.
- W2912246633 hasConcept C90924648 @default.
- W2912246633 hasConceptScore W2912246633C126322002 @default.
- W2912246633 hasConceptScore W2912246633C143998085 @default.
- W2912246633 hasConceptScore W2912246633C2776305933 @default.
- W2912246633 hasConceptScore W2912246633C2776694085 @default.
- W2912246633 hasConceptScore W2912246633C2776755627 @default.
- W2912246633 hasConceptScore W2912246633C2779338263 @default.
- W2912246633 hasConceptScore W2912246633C2779429289 @default.
- W2912246633 hasConceptScore W2912246633C2780653079 @default.
- W2912246633 hasConceptScore W2912246633C71924100 @default.
- W2912246633 hasConceptScore W2912246633C90924648 @default.
- W2912246633 hasIssue "Supplement 1" @default.
- W2912246633 hasLocation W29122466331 @default.
- W2912246633 hasOpenAccess W2912246633 @default.
- W2912246633 hasPrimaryLocation W29122466331 @default.
- W2912246633 hasRelatedWork W1971727742 @default.
- W2912246633 hasRelatedWork W1998212570 @default.
- W2912246633 hasRelatedWork W2094927988 @default.
- W2912246633 hasRelatedWork W2143803333 @default.
- W2912246633 hasRelatedWork W2365471278 @default.
- W2912246633 hasRelatedWork W2383461898 @default.
- W2912246633 hasRelatedWork W2391661238 @default.
- W2912246633 hasRelatedWork W2556511286 @default.
- W2912246633 hasRelatedWork W2576449545 @default.
- W2912246633 hasRelatedWork W2805808559 @default.